Clinical Trials Directory

Trials / Completed

CompletedNCT03486912

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
155 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage characterized by normal liver tissue being replaced by scar tissue).

Conditions

Interventions

TypeNameDescription
DRUGBMS-986036Specified dose on specified days.
OTHERPlaceboSpecified dose on specified days.

Timeline

Start date
2018-06-12
Primary completion
2020-10-08
Completion
2021-09-14
First posted
2018-04-03
Last updated
2022-10-13
Results posted
2022-10-13

Locations

91 sites across 2 countries: United States, Japan

Regulatory

Source: ClinicalTrials.gov record NCT03486912. Inclusion in this directory is not an endorsement.